Novartis AG (FRA:NOTA) Stock Based Compensation: €977 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NOTA Novartis AG FRA:NOTA
81 GF Score
Price €134.00
GF Value €111.83
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novartis AG Stock Based Compensation?

Novartis AG FRA:NOTA 81 Stock Based Compensation is €977 Mil as of Mar. 2026. GuruFocus rates FRA:NOTA with a GF Score™ of 81/100 and a GF Value™ of €111.83 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Novartis AG's Stock Based Compensation for the three months ended in Mar. 2026 was €262 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was €977 Mil.

Novartis AG Stock Based Compensation Related Terms

Novartis AG Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Novartis AG's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG Stock Based Compensation Chart

Novartis AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 619.50 746.70 793.21 997.02 935.98

Novartis AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 242.35 231.49 228.34 255.35 262.10
FRA:NOTA
81GF Score
Novartis AG FRA:NOTA
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novartis AG Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €977 Mil.

What does a Stock Based Compensation of €977 Mil mean?
Novartis AG (FRA:NOTA) has a Stock Based Compensation of €977 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Novartis AG and its competitors.
Is Novartis AG's Stock Based Compensation too high?
Novartis AG's current Stock Based Compensation is €977 Mil. Overall, Novartis AG has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's Stock Based Compensation compare to LLY and JNJ?
Novartis AG's Stock Based Compensation of €977 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Novartis AG and its competitors. Novartis AG's current Stock Based Compensation is €977 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Based on GuruFocus' analysis, Novartis AG (FRA:NOTA) is currently considered Modestly Overvalued. The stock's GF Value™ is €111.83, compared to a current price of €134.00 — trading 19.8% above its estimated fair value. The current Stock Based Compensation is €977 Mil. Novartis AG's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Novartis AG (FRA:NOTA), the current Stock Based Compensation is €977 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis AG (FRA:NOTA) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of €134.00 is trading 19.8% above its estimated GF Value™ of €111.83. GuruFocus considers Novartis AG to be Modestly Overvalued.

Key valuation signals for FRA:NOTA:

  • Stock Based Compensation: €977 Mil
  • GF Value™: €111.83 vs. price of €134.00 (19.8% above fair value)
  • GF Score™: 81/100 with 7 warning signs

No single metric tells the full story. See the FRA:NOTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
81GF Score

Get the complete analysis for FRA:NOTA

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€134.00
Price
€111.83
GF Value